As a result of the agreement, Syrrx shall be the only company authorised to use MolSoft VLS technology in combination with structural proteomics capabilities. MolSoft will, however, continue to provide VLS services directly to major pharmaceutical and biotechnology companies.
Syrrx uses an array of proprietary robotic technologies to automate and streamline multiple steps in the protein structure determination process, resulting in the determination of hundreds of protein structures each year. MolSoft's technology then takes Syrrx discoveries one step closer to medical breakthroughs by using protein structures to create novel drugs.
MolSoft's VLS technology uses a supercomputer to simulate the interaction between proteins as potential drug targets and small molecules as potential drugs. The proteins and small molecules are "fitted" together in the computer to identify those small molecules which might become future drugs. More than 1 million compounds can be tested each day using MolSoft technology.
"Our new algorithms are trained to solve the global energy optimisation problem of highly complex systems", commented Maxim Totrov, who is the principal scientist and the scientific co-founder of Molsoft. "Syrrx's robotics", added Wendell Wierenga, CEO of Syrrx, "leveraged together with MolSoft's VLS technology, uniquely positions Syrrx to assume the lead in the structural proteomics space, and ultimately, to design drugs rapidly."
MolSoft has been developing breakthrough software tools for molecular modelling, bio-informatics, and computer-aided drug discovery since 1994. MolSoft's technology is used by major academic institutions, government organisations, and pharmaceutical companies, including the Genomics Institute of the Novartis Research Foundation, the National Institutes of Health, the Karolinska Institute in Sweden, New York University, Structural Bioinformatics Inc., eBioinformatics, Pharmacia, SmithKline Beecham, and Bristol-Myers Squibb.